Renasant Bio

Renasant Bio Launches to Pioneer Next-Generation Disease-Modifying Small Molecule Treatments for ADPKD

Renasant Bio researches treatments for autosomal dominant polycystic kidney disease (ADPKD) by developing small molecule correctors and potentiators targeting polycystin 1 and 2 (PC1/2).

Renasant Bio’s Privacy Policy explains how the company collects, uses, and shares personal information through its website, social media, and marketing activities.

Emily Conley discusses developing small-molecule therapies to treat a rare kidney disease. The conversation explores scientific approaches targeting genetic defects in kidney function. Conley highlights the potential of precision medicine in addressing underserved patient populations.

Dec 2025Timmerman ReportNews article

Renasant Bio launches to develop small-molecule treatments targeting autosomal dominant polycystic kidney disease (ADPKD). The company advances corrector and potentiator programs aimed at addressing the disease’s underlying biology across multiple genetic mutations. This approach seeks to modify disease progression rather than merely managing symptoms.

Nov 2025BioSpaceNews article

Renasant Bio launches with a focus on developing treatments for polycystic kidney disease. The company secures $54.5 million in funding to advance therapies aimed at restoring protein function in affected patients. This initiative targets a genetic disorder impacting kidney health.

Jul 2025Chemical & Engineering NewsNews article

Renasant Bio, a Berkeley-based biotech, secures **$54.5 million in seed funding** to develop **corrector and potentiator medicines** for kidney disease, aiming to replicate Vertex Pharmaceuticals’ approach. The company focuses on novel therapies targeting cystic fibrosis and related conditions. Investors back its potential to advance precision treatments in nephrology.

Jul 2025Endpoints NewsNews article